Insmed Appoints David R. Brennan to Its Board of Directors
29 Mai 2014 - 3:36PM
Marketwired
Insmed Appoints David R. Brennan to Its Board of Directors
Pharmaceutical Executive With More Than 37 Years of Industry
Experience
MONMOUTH JUNCTION, NJ--(Marketwired - May 29, 2014) - Insmed
Incorporated (NASDAQ: INSM) today announced the appointment of
David R. Brennan to its Board of Directors. Mr. Brennan has
more than 37 years of experience in the pharmaceutical industry and
was formerly the Chief Executive Officer of AstraZeneca
PLC.
"We are delighted to welcome David to the Insmed
Board. David's deep and diverse set of global operating
experiences will be invaluable as we build Insmed into a global
commercial biopharmaceutical company with novel therapies across
orphan, pulmonary and infectious diseases," stated Donald J.
Hayden, Jr., Chairman of the Board of Insmed.
In accepting this appointment, Mr. Brennan stated, "I am excited
to join Insmed at this stage in its growth. My personal
interests are in companies where the products can make a meaningful
difference in treating unmet medical needs. Given their focus
on orphan diseases and their most recent clinical data in
nontuberculous mycobacteria lung infections, I believe Insmed has a
unique opportunity to improve the lives of patients. I look
forward to working with the Insmed Board and leadership team to
further the company's strategic objectives to become an industry
leader."
From 2006 to 2012 Mr. Brennan served as Chief Executive Officer
of AstraZeneca, a leading global pharmaceutical company with more
than $27 billion in revenue and 60,000 employees in 2012. Mr.
Brennan started his career in sales at Merck and Co. and quickly
ascended into management roles at Merck. Mr. Brennan continued
to take on increasing managerial and executive roles at Astra Merck
and then Astra Pharmaceuticals. Mr. Brennan became an
executive at AstraZeneca when Astra and Zeneca merged in
1999. Mr. Brennan has been an executive member of several
leading industry associations, including former Chairman of
Pharmaceutical Research and Manufacturers of America (PhRMA),
executive board member of the European Federation of
Pharmaceuticals Industries and Associations (EFPIA) and former
President of the International Federation of Pharmaceuticals
Manufacturers and Associations (IFPMA). Mr. Brennan received a
bachelor's degree in business administration from Gettysburg
College.
About Insmed
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious lung diseases.
Insmed is focused on the development and commercialization of
ARIKAYCE™, or liposomal amikacin for inhalation, for at least two
identified orphan patient populations: patients with nontuberculous
mycobacteria (NTM) lung infections and cystic fibrosis (CF)
patients with Pseudomonas aeruginosa lung infections. For more
information, please visit http://www.insmed.com.
Forward-looking Statements
This release contains forward-looking statements. Words,
and variations of words, such as "intend," "expect," "will,"
"anticipate," "believe," "continue," "propose" and similar
expressions are intended to identify forward-looking
statements. Investors are cautioned that such statements in
this release, including statements relating to the status, results
and timing of clinical trials and clinical data, the anticipated
benefits of Insmed's products, the anticipated timing of regulatory
submissions, and the ability to obtain required regulatory
approvals, bring products to market and successfully commercialize
products constitute forward-looking statements that involve risks
and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. Such
risks and uncertainties include, without limitation, failure or
delay of European, Canadian, U.S. Food and Drug Administration and
other regulatory reviews and approvals, competitive developments
affecting the Company's product candidates, delays in product
development or clinical trials or other studies, patent disputes
and other intellectual property developments relating to the
Company's product candidates, unexpected regulatory actions, delays
or requests, the failure of clinical trials or other studies or
results of clinical trials or other studies that do not meet
expectations, the fact that subsequent analyses of clinical trial
or study data may lead to different (including less favorable)
interpretations of trial or study results or may identify important
implications of a trial or study that are not reflected in
Company's prior disclosures, and the fact that trial or study
results or subsequent analyses may be subject to differing
interpretations by regulatory agencies, the inability to
successfully develop the Company's product candidates or receive
necessary regulatory approvals, the ability to obtain Breakthrough
Therapy Designation for ARIKAYCE in the U.S., the inability to make
product candidates commercially successful, changes in anticipated
expenses, changes in the Company's financing requirements or
ability to raise additional capital, and other risks and challenges
detailed in the Company's filings with the U.S. Securities and
Exchange Commission, including, without limitation, its Annual
Report on Form 10-K for the year ended December 31, 2013 and its
subsequent quarterly reports on Form 10-Q. Investors are
cautioned not to place undue reliance on any forward-looking
statements that speak only as of the date of this news
release. The Company undertakes no obligation to update these
forward-looking statements to reflect events or circumstances or
changes in its expectations.
Contacts: LHA Anne Marie Fields Senior Vice President
212-838-3777 afields@lhai.com Bruce Voss Managing Director
310-691-7100 bvoss@lhai.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024